Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2008-06-24
2008-06-24
Habte, Kahsay T. (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C544S236000
Reexamination Certificate
active
07390808
ABSTRACT:
The present invention relates to inhibitors of GSK-3 and methods for producing these inhibitors. The invention also provides pharmaceutical compositions comprising the inhibitors and methods of utilizing those compositions in the treatment and prevention of various disorders, such as diabetes and Alzheimer's disease. In addition, the invention relates to molecules or molecular complexes which comprise binding pockets of GSK-3β or its homologues. The invention relates to a computer comprising a data storage medium encoded with the structure coordinates of such binding pockets. The invention also relates to methods of using the structure coordinates to solve the structure of homologous proteins or protein complexes. The invention relates to methods of using the structure coordinates to screen for and design compounds that bind to GSK-3β protein or homologues thereof. The invention also relates to crystallizable compositions and crystals comprising GSK-3β protein or GSK-3β protein complexes.
REFERENCES:
patent: 4886646 (1989-12-01), Carter et al.
patent: 5096676 (1992-03-01), McPherson et al.
patent: 5130105 (1992-07-01), Carter et al.
patent: 5221410 (1993-06-01), Kushner et al.
patent: 5353236 (1994-10-01), Subbiah
patent: 5400741 (1995-03-01), DeTitta et al.
patent: 6162613 (2000-12-01), Su et al.
patent: 6387641 (2002-05-01), Bellon et al.
patent: WO 92/14211 (1992-08-01), None
patent: WO 93/02209 (1993-02-01), None
patent: WO 94/25860 (1994-11-01), None
patent: WO 98/35048 (1998-08-01), None
patent: WO 99/65897 (1999-12-01), None
patent: WO 00/12497 (2000-03-01), None
patent: WO 00/38675 (2000-07-01), None
patent: WO 02/24694 (2002-03-01), None
patent: WO 02/24893 (2002-03-01), None
Fawzy et al. Asian Journal of Chemistry (1992), 4(3), 500-7.
Said et al. Asian Journal of Chemistry (1989), 1(4), 376-383.
Deeb et al. Heterocycles (1991), vol. 32, No. 5. 895-900.
Seada et al. Journal of the Chinese Chemical Society (Taipei, Taiwan) (1989), 36(3), 241-9.
Adams, J.A., “Kinetic and Catalytic Mechanisms of Protein Kinases,”Chem. Rev., 101: 2271-2290 (2001).
Balbes, L.M., et al., “A Perspective of Modern Methods in Computer-Aided Drug Design,” in “Reviews in Computational Chemistry,” K.B. Lipkowitz and D.B. Boyd, Eds., VCH Publishers, New York, 5: 337-379 (1994).
Bartlett, P.A., et al., “CAVEAT: A Program to Facilitate the Structure-Derived Design of Biologically Active Molecules,” in “Molecular Recognition in Chemical and Biological Problems,” S.M. Roberts, Ed., Royal Society of Chemistry, Special Publication No. 78: 182-196 (1989).
Bellon, S., et al., “The Structure of Phosphorylated P38γ is Monomeric and Reveals a Conserved Activation-Loop Conformation,”Structure, 7: 1057-1065 (1999).
Böhm, H.-J., “The Computer Program LUDI: A New Method for the De Novo Design of Enzyme Inhibitors,”J. Comp. Aid. Molec. Design, 6: 61-78 (1992).
Brown, N.R., et al., “The Structural Basis for Specificity of Substrate and Recruitment Peptides for Cyclin-dependent Kinases,”Nature Cell Biol., 1: 438-443 (1999).
Brownlees, J. et al., “Tau Phosphorylation in Transgenic Mice Expressing Glycogen Synthase Kinase-3β Transgenes,”NeuroReport, 8: 3251-3255 (1997).
Coghlan, M.P., et al., “Selective Small Molecule Inhibitors of Glycogen Synthase Kinase-3 Modulate Glycogen Metabolism and Gene Transcription,”Chemistry&Biology, 7: 793-803 (2000).
Cohen, N.C., et al., “Molecular Modeling Software and Methods for Medicinal Chemistry,”J. Med. Chem., 33: 883-894 (1990).
Cohen, P., “Dissection of the Protein Phosphorylation Cascades Involved in Insulin and Growth Factor Action,”Biochem. Soc. Trans., 21: 555-567 (1993).
Collaborative Computational Project, No. 4, “TheCCP4 Suite: Programs for Protein Crystallography,”Acta Cryst., D50: 760-763 (1994).
Cross, D.A.E., et al., “The Inhibition of Glycogen Synthase Kinase-3 by Insulin or Insulin-Like Growth Factor 1 in the Rat Skeletal Muscle Cell Line L6 is Blocked by Wortmannin, but not by Rapamycin: Evidence that Wortmannin Blocks Activation of the Mitogen-Activated Protein Kinase Pathway in L6 Cells between Ras and Raf,”Biochem. J., 303: 21-26 (1994).
Deeb, A. and Said, S.A., “Studies on Polyazaindenes Synthesis of Several New Condensed Pyridazine Derivatives,”Collect. Czech. Chem. Commun., 55: 2795-2799 (1990).
Ding, V.W., et al., “Differential Regulation of Glycogen Synthase Kinase 3β by Insulin and Wnt Singaling,”J. Biol. Chem., 275: 32475-32481 (2000).
Eisen, M.B., et al., “HOOK: A Program for Finding Novel Molecular Architectures that Satisfy the Chemical and Steric Requirements of a Macromolecule Binding Site,”Proteins Struct. Funct. Genet., 19: 199-221 (1994).
Fang, X., et al., “Phosphorylation and Inactivation of Glycogen Synthase Kinase 3 by Protein Kinase A,”Proc. Natl. Acad. Sci. USA, 97: 11960-11965 (2000).
Fox, T., et al., “A Single Amino Acid Substitution Makes ERK2 Susceptible to Pyridinyl Imidazole Inhibitors of p38 MAP Kinase,”Protein Sci., 7: 2249-2255 (1998).
Gerstein, M., and Altman, R.B., “Average Core Structures and Variability Measures for Protein Families: Application to the Immunoglobulins,”J. Mol. Biol., 251: 161-175 (1995).
Gillet, V., et al., “SPROUT: A Program for Structure Generation,”J. Comp. Aid. Molec. Design, 7: 127-153 (1993).
Goodford, P.J., “A Computational Procedure for Determining Energetically Favorable Binding Sites on Biologically Important Macromolecules,”J. Med. Chem., 28: 849-857 (1985).
Goodsell, D.S., and Olson, A.J., “Automated Docking of Substrates to Proteins by Simulated Annealing,”Proteins Struct. Funct. Genet., 8: 195-202 (1990).
Guida, W.C., “Software for Structure-Based Drug Design,”Curr. Opin. Struct. Biology, 4: 777-781 (1994).
Hanks, S.K., et al., “The Protein Kinase Family: Conserved Features and Deduced Phylogeny of the Catalytic Domains,”Science, 241: 42-52 (1988).
Hanks, S.K. and Quinn, A.M., “Protein Kinase Catalytic Domain Sequence Database: Identification of Conserved Features of Primary Structure and Classification of Family Members,”Methods in Enzymology, 200: 38-62 (1991).
Hanks, S.K. and Hunter, T., “The Eukaryotic Protein Kinase Superfamily: Kinase (Catalytic) Domain Structure and Classification,”FASEB J., 9: 576-596 (1995).
Haq, S., et al., “Glycogen Synthase Kinase-3β Is a Negative Regulator of Cardiomyocyte Hypertrophy,”J. Cell Biol., 151: 117-129 (2000).
Hoeflich, K.P., et al., “Requirement for Glycogen Synthase Kinase-3β in Cell Survival and NF-κB Activation,”Nature, 406: 86-90 (2000).
Ikeda, S., et al., “Axin, a Negative Regulator of the Wnt Signaling Pathway, Forms a Complex with GSK-3β and β-Catenin and Promotes GSK-3β-Dependent Phosphorylation of β-Catenin,”EMBO J., 17: 1371-1384 (1998).
Iyoda, M., et al., “Synthesis of Riccardin B by Nickel-Catalyzed Intramolecular Cyclization,”Tetrahedron Letters, 26: 4777-4780 (1985).
Kim, L. and Kimmel, A.R., “GSK3, a Master Switch Regulating Cell-Fate Specification and Tumorigenesis,”Current Opinion in Genetics&Development, 10: 508-514 (2000).
Klein, P.S. and Melton, D.A., “A Molecular Mechanism for the Effect of Lithium on Development,”Proc. Natl. Acad. Sci. USA, 93: 8455-8459 (1996).
Kuntz, I.D., et al., “A Geometric Approach to Macromolecule-Ligand Interactions,”J. Mol. Biol., 161: 269-288 (1982).
Kuret, J., et al., “Multisite Phosphorylation of Glycogen Synthase from Rabbit Skeletal Muscle: Identification of the Sites Phosphorylated by Casein Kinase-I,”Eur. J. Biochem., 151: 39-48 (1985).
Lauri, G. and Bartlett, P.A., “CAVEAT: A Program to Facilitate the Design of Organ
Arnost Michael J.
Green Jeremy
Habte Kahsay T.
Haley Jr. James F.
Kercher Michele A.
Ropes & Gray LLP
Vertex Pharmaceuticals Incorporated
LandOfFree
Inhibitors of GSK-3 and crystal structures of GSK-3β... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Inhibitors of GSK-3 and crystal structures of GSK-3β..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Inhibitors of GSK-3 and crystal structures of GSK-3β... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2809619